Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 14/20 | 0.65 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631734 | 1.00 | HCAR2 (0.65) | HCAR2HSD17B1KDM4EMEN1MAPT | |
| SCHEMBL13673279 | 1.00 | HCAR2 (0.65) | HCAR2HSD17B1KDM4EMEN1MAPT | |
| SCHEMBL13638113 | 0.99 | HCAR2 (0.67) | HCAR2HSD17B1KDM4EMEN1MAPT | |
| SCHEMBL13631728 | 0.99 | HCAR2 (0.67) | HCAR2HSD17B1KDM4EMEN1MAPT | |
| SCHEMBL13631695 | 0.95 | HCAR2 (0.60) | HCAR2HSD17B1KDM4EMEN1MAPT | |
| SCHEMBL13638167 | 0.81 | HCAR2 (0.97) | HCAR2 | |
| SCHEMBL13631736 | 0.81 | HCAR2 (0.97) | HCAR2 | |
| SCHEMBL13631729 | 0.79 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL13638166 | 0.79 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL4498053 | 0.79 | HCAR2 (0.43) | HCAR2HSD17B1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612106-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | HCAR2 300/4885HSD17B1 88/4885KDM4E 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.